Morningstar

Janus Henderson Global Life Sciences Fund Class I JFNIX

Morningstar Medalist Rating
Medalist Rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 86.28  /  −0.14 %
  • Total Assets 5.8B
  • Adj. Expense Ratio
    0.780%
  • Expense Ratio 0.780%
  • Distribution Fee Level Below Average
  • Share Class Type Institutional
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.42%
  • Turnover 30%

USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0

Morningstar’s Analysis JFNIX

Will JFNIX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable JFNIX’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the JFNIX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of JFNIX’s parent organization’s priorities and whether they’re in line with investors’ interests.

One of our high-conviction healthcare offerings.

Senior Analyst Ramanand Kothari

Ramanand Kothari

Senior Analyst

Summary

Janus Henderson Global Life Sciences benefits from an exceptional lead manager, strong support resources, and a consistently applied robust investment process with prudent risk management, underpinning its Above Average People and Process Pillar ratings.

by Ramanand Kothari
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JFNIX

More JFNIX Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 42.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.05 545M
Healthcare

Johnson & Johnson

7.48 450M
Healthcare

AbbVie Inc

4.63 279M
Healthcare

UnitedHealth Group Inc

4.33 261M
Healthcare

AstraZeneca PLC

3.50 211M
Healthcare

Thermo Fisher Scientific Inc

2.92 176M
Healthcare

Novartis AG ADR

2.78 167M
Healthcare

Roche Holding AG 0%

2.63 159M
Corporate

argenx SE ADR

2.55 154M
Healthcare

Abbott Laboratories

2.36 142M
Healthcare

Sponsor Center